Table of Contents Author Guidelines Submit a Manuscript
Critical Care Research and Practice
Volume 2012, Article ID 427607, 8 pages
http://dx.doi.org/10.1155/2012/427607
Review Article

Manipulation of the Complement System for Benefit in Sepsis

1Department of Pathology, University of Michigan Medical School, 1301 Catherine Road, P.O. Box 5602, Ann Arbor, MI 48109-5602, USA
2Department of Anesthesiology and Intensive Care Medicine, University Hospital Jena, 07747 Jena, Germany

Received 28 September 2011; Accepted 6 November 2011

Academic Editor: Howard L. Corwin

Copyright © 2012 Peter A. Ward et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. A. Ward, “The harmful Role of C5a on innate immunity in sepsis,” Journal of Innate Immunity, vol. 2, no. 5, pp. 439–445, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. M. S. Huber-Lang, E. M. Younkin, J. V. Sarma et al., “Complement-induced impairment of innate immunity during sepsis,” Journal of Immunology, vol. 169, no. 6, pp. 3223–3231, 2002. View at Google Scholar · View at Scopus
  3. N. C. Riedemann, R. F. Guo, T. A. Neff et al., “Increased C5a receptor expression in sepsis,” Journal of Clinical Investigation, vol. 110, no. 1, pp. 101–108, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. D. Rittirsch, M. S. Huber-Lang, M. A. Flierl, and P. A. Ward, “Immunodesign of experimental sepsis by cecal ligation and puncture,” Nature Protocols, vol. 4, no. 1, pp. 31–36, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. D. Rittirsch, M. A. Flierl, B. A. Nadeau et al., “Functional roles for C5a receptors in sepsis,” Nature Medicine, vol. 14, no. 5, pp. 551–557, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Huber-Lang, J. V. Sarma, F. S. Zetoune et al., “Generation of C5a in the absence of C3: a new complement activation pathway,” Nature Medicine, vol. 12, no. 6, pp. 682–687, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. J. H. Stevens, P. O'Hanley, J. M. Shapiro et al., “Effects of anti-C5a antibodies on the adult respiratory distress syndrome in septic primates,” Journal of Clinical Investigation, vol. 77, no. 6, pp. 1812–1816, 1986. View at Google Scholar
  8. D. H. Hangen, J. H. Stevens, P. S. Satoh, E. W. Hall, P. T. O'Hanley, and T. A. Raffin, “Complement levels in septic primates treated with anti-C5a antibodies,” Journal of Surgical Research, vol. 46, no. 3, pp. 195–199, 1989. View at Google Scholar · View at Scopus
  9. U. Höpken, M. Mohr, A. Strüber et al., “Inhibition of interleukin-6 synthesis in an animal model of septic shock by anti-C5a monoclonal antibodies,” European Journal of Immunology, vol. 26, no. 5, pp. 1103–1109, 1996. View at Publisher · View at Google Scholar
  10. M. Mohr, U. Höpken, M. Oppermann et al., “Effects of anti-C5a monoclonal antibodies on oxygen use in a porcine model of severe sepsis,” European Journal of Clinical Investigation, vol. 28, no. 3, pp. 227–234, 1998. View at Publisher · View at Google Scholar
  11. G. Smedegard, L. Cui, and T. E. Hugli, “Endotoxin-induced shock in the rat. A role for C5a,” American Journal of Pathology, vol. 135, no. 3, pp. 489–497, 1989. View at Google Scholar · View at Scopus
  12. B. J. Czermak, V. Sarma, C. L. Pierson et al., “Protective effects of C5a blockade in sepsis,” Nature Medicine, vol. 5, no. 7, pp. 788–792, 1999. View at Publisher · View at Google Scholar · View at Scopus
  13. M. S. Huber-Lang, J. V. Sarma, S. R. McGuire et al., “Protective effects of anti-C5a peptide antibodies in experimental sepsis,” The FASEB Journal, vol. 15, no. 3, pp. 568–570, 2001. View at Google Scholar · View at Scopus
  14. M. Huber-Lang, V. J. Sarma, K. T. Lu et al., “Role of C5a in multiorgan failure during sepsis,” Journal of Immunology, vol. 166, no. 2, pp. 1193–1199, 2001. View at Google Scholar · View at Scopus
  15. M. Allegretti, A. Moriconi, A. R. Beccari et al., “Targeting C5a: recent advances in drug discovery,” Current Medicinal Chemistry, vol. 12, no. 2, pp. 217–236, 2005. View at Google Scholar · View at Scopus
  16. M. Hiramatsu, R. S. Hotchkiss, I. E. Karl, and T. G. Buchman, “Cecal ligation and puncture (CLP) induces apoptosis in thymus, spleen, lung, and GUT by an endotoxin and TNF- independent pathway,” Shock, vol. 7, no. 4, pp. 247–253, 1997. View at Google Scholar · View at Scopus
  17. R. S. Hotchkiss, P. E. Swanson, J. P. Cobb, A. Jacobson, T. G. Buchman, and I. E. Karl, “Apoptosis in lymphoid and parenchymal cells during sepsis: findings in normal and T- and B-celldeficient mice,” Critical Care Medicine, vol. 25, no. 8, pp. 1298–1307, 1997. View at Publisher · View at Google Scholar · View at Scopus
  18. R. S. Hotchkiss, K. W. Tinsley, P. E. Swanson et al., “Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans,” Journal of Immunology, vol. 166, no. 11, pp. 6952–6963, 2001. View at Google Scholar · View at Scopus
  19. R. S. Hotchkiss, K. C. Chang, P. E. Swanson et al., “Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte,” Nature Immunology, vol. 1, no. 6, pp. 496–501, 2000. View at Google Scholar · View at Scopus
  20. R. F. Guo, M. Huber-Lang, X. Wang et al., “Protective effects of anti-C5a in sepsis-induced thymocyte apoptosis,” Journal of Clinical Investigation, vol. 106, no. 10, pp. 1271–1280, 2000. View at Google Scholar · View at Scopus
  21. N. C. Riedemann, R. F. Guo, I. J. Laudes et al., “C5a receptor and thymocyte apoptosis in sepsis,” The FASEB Journal, vol. 16, no. 8, pp. 887–888, 2002. View at Google Scholar · View at Scopus
  22. D. E. Hammerschmidt, L. J. Weaver, and L. D. Hudson, “Association of complement activation and elevated plasma-C5a with adult respiratory distress syndrome. Pathophysiological relevance and possible prognostic value,” The Lancet, vol. 1, no. 8175, pp. 947–949, 1980. View at Google Scholar · View at Scopus
  23. J. S. Solomkin, M. K. Jenkins, R. D. Nelson, D. Chenoweth, and R. L. Simmons, “Neutrophil dysfunction in sepsis. II. Evidence for the role of complement activation products in cellular deactivation,” Surgery, vol. 90, no. 2, pp. 319–327, 1981. View at Google Scholar · View at Scopus
  24. C. Caliezi, S. Zeerleder, M. Redondo et al., “C1-inhibitor in patients with severe sepsis and septic shock: beneficial effect on renal dysfunction,” Critical Care Medicine, vol. 30, no. 8, pp. 1722–1728, 2002. View at Google Scholar · View at Scopus
  25. T. E. Van Dyke, “Role of the neutrophil in oral disease: receptor deficiency in leukocytes from patients with juvenile periodontitis,” Reviews of Infectious Diseases, vol. 7, no. 3, pp. 419–425, 1985. View at Google Scholar · View at Scopus
  26. R. J. Kelly, A. Hill, L. M. Arnold et al., “Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival,” Blood, vol. 117, no. 25, pp. 6786–6792, 2011. View at Publisher · View at Google Scholar
  27. M. A. Flierl, D. Rittirsch, B. A. Nadeau et al., “Functions of the complement components C3 and C5 during sepsis,” FASEB Journal, vol. 22, no. 10, pp. 3483–3490, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. F. Fredslund, N. S. Laursen, P. Roversi et al., “Structure of and influence of a tick complement inhibitor on human complement component 5,” Nature Immunology, vol. 9, no. 7, pp. 753–760, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. C. Sheridan, “TeGenero fiasco prompts regulatory rethink,” Nature Biotechnology, vol. 24, no. 5, pp. 475–476, 2006. View at Publisher · View at Google Scholar · View at Scopus